Presage Biosciences

Presage aims to enhance the process of drug development and targeting by utilizing their patented CIVO® (Comparative In Vivo Oncology) technology, which administers microdoses of multiple drugs to various areas within a patient's tumor. The observation of molecular and cellular responses to drugs and combinations within the natural tumor environment holds the potential to offer a more comprehensive understanding of tumor biology, encompassing the patient's own immune system, tumor microenvironment, and genetic makeup. Ultimately, the mission of Presage is to advance the development of new drugs and targeted therapies, with the objective of providing more efficacious treatments for cancer patients.